Lilly's Retatrutide Lawsuits: Enforcing a Drug Nobody Has Approved

Eli Lilly spent this week in court defending a molecule no regulator on Earth has approved — and that Lilly itself hasn't even filed.

And that was the smaller surprise. Let's take the week apart.

Welcome to The Pharma Closeout Week in Review for Sunday, August 16th. I'm Alex Mercer.

And I'm Maya Patel. A lot happened this week that deserves a second look. Let's get into it.

Six lawsuits. That's the number that defines the week. Eli Lilly filed six suits on Wednesday against sellers of black-market retatrutide — compounders, wellness clinics, online peptide vendors — alleging they're moving fake, impure, or mis-dosed versions of the company's experimental triple-G obesity medicine. Lilly says it has already referred more than 200 people and entities to regulators, licensing boards, and law enforcement. A company is now litigating to protect a product it hasn't asked the FDA to approve.

Before the filing. Sit with that sequence.

That IS the story. Retatrutide has produced weight loss in Lilly's research that in some cases tracks with bariatric surgery. The application isn't planned until next year. And in the gap between that data entering public consciousness and the regulatory clock starting, an entire supply chain assembled itself around a product that commercially does not exist.

Assembled is generous — it was already standing. The compounding ecosystem scaled during the GLP-1 shortage years and kept taking share after the FDA declared the shortage over and told them to stop. Retatrutide didn't build that channel. It walked into one running at capacity, with customer lists, payment rails, and a phrase doing enormous legal work: "research use only." Lilly named that language specifically in several of these suits.

Which tells you these aren't shadowy operators hiding. The defendants include Striker Pharmacy — a compounding pharmacy CBS News found advertising the drug back in June — plus Aesthetic Envy, Astra Peptides, Legendary Peptides, Texas Peptides, and Lone Star Peptide. Now hold that against the scale. Lilly says it has flagged more than 14,000 websites, ads, social posts, and product listings across more than a hundred countries. Six suits against that denominator isn't enforcement. It's a warning shot with a docket number.

Here's where I'd push on your framing, though. You're reading this as brand protection ahead of a launch. I think the exposure is clinical, and it's more urgent than the commercial version. Every adverse event out of an impure or mis-dosed copy gets reported, discussed, and searched under one word — retatrutide. Lilly controls the safety database inside its own trials. It controls nothing about what a reviewer, a payer, or a prescriber has already absorbed before the application is even in the building.

I'll take most of that. Where I hold my ground is that you can't separate them — the commercial risk here IS the clinical contamination. But your point about timing is the tell. If this were about share, you sue at launch. Suing now, pre-submission, says the asset they're defending is the record.

Then the honest read is that this isn't a brand action at all. It's regulatory hygiene wearing a brand action's clothes — and it tells you Lilly already expects the review to happen in a room where the black market is part of the conversation.

And that room is not neutral. Lilly is asking courts, regulators, and law enforcement for help at a moment when the top U.S. health official appears inclined to give freer rein to unreviewed substances. In July, an FDA advisory panel endorsed broader use of six peptides without substantial evidence of safety and effectiveness — that's BioPharma Dive's reporting. So Lilly is privately funding an enforcement function it can't assume the agency will perform for it.

Can I sharpen one word everyone's using loosely? Mis-dosed.

Go ahead.

There is no approved label for retatrutide. No titration schedule, no ceiling dose, no reduction guidance for renal impairment or for the patients most likely to need it. So "mis-dosed" isn't a deviation from a reference standard — there is no reference standard yet. Whatever a clinic is injecting, nobody in that room, including the person holding the syringe, has an authoritative number to be wrong against. That's a categorically different risk than a compounded copy of an approved drug, and I don't think the coverage has drawn that line.

That reframes the litigation entirely.

It reframes what Lilly is actually asking the court to protect. Not a price. A dose-response relationship they haven't finished establishing.

The competitive read: if you're running commercial strategy on any high-demand chronic therapy heading into a filing, this week made pre-approval channel enforcement a line item in the launch plan — not a legal afterthought. Lilly just built the template, and everyone behind them in obesity is going to copy it.

The open question is whether litigation is even the right instrument. Six suits against 14,000 listings does nothing on volume. What it might do is hand licensing boards and prosecutors a documented record they can act on faster than a court can. And what I'll be watching next year isn't the approval decision. It's whether the label and the risk management program that come with it end up shaped by a market that got there first.

Which is the thread running through this whole week in review. Four stories, one axis: how much evidence does someone need before they act. And in every case, the answer moved earlier.

Start with Bristol Myers Squibb, because that one has consequences well past its own indication. Zenbexus — iberdomide — took accelerated approval Thursday with daratumumab and dexamethasone in myeloma patients with at least one prior line. The number is 41 against 21: MRD-negative complete response of 41% on the iberdomide regimen versus 21% on daratumumab, bortezomib and dexamethasone, at a median 16 months of follow-up. Per BMS, that's the first FDA-approved CELMoD in myeloma, and the first approval in relapsed or refractory disease built on MRD-negative complete response.

A surrogate endpoint carrying an accelerated approval in the most crowded relapsed setting in oncology. William Blair models north of a billion in U.S. sales by early 2031.

And here's what I think people are skating past. EXCALIBER excluded patients refractory to prior anti-CD38 antibody therapy or to bortezomib. So that 41-versus-21 separation was generated in a population that hadn't failed either backbone — while the second-line patient a community hematologist actually sees in 2026 is very often CD38-exposed already.

So the comparator arm isn't the real-world comparator.

The comparator arm isn't the real-world patient. That doesn't invalidate the result — it defines the edge of it. And that sentence belongs in every competing launch team's deck by Tuesday.

Push on the confirmatory structure, though, because I read that as unusually tight for an accelerated approval.

It is, and that's why I'd call it a deliberate precedent rather than an accommodation. EXCALIBER carries dual primary endpoints — MRD negativity and progression-free survival — and the trial is still running. So the confirmation of clinical benefit comes out of the same study that produced the approval, with that PFS readout expected this year. The agency isn't waiting on a trial that hasn't enrolled a patient. It's waiting on one already in flight.

That's a materially different risk profile than the accelerated approvals that got walked back.

Materially. Though it arrives with boxed warnings for thromboembolism and embryo-fetal toxicity, and a restricted risk management program — which constrains where this actually gets used regardless of what the efficacy says. Label breadth and practical breadth are not the same thing here.

Same axis, different disease. Taiho Oncology and Cullinan Therapeutics said Wednesday that zipalertinib plus chemotherapy hit its primary endpoint in first-line EGFR exon 20 insertion lung cancer — statistically significant, clinically meaningful improvement in progression-free survival — and investigators unblinded the trial at an early data check because the result was that clear.

Unblinding early is the data point. They released no curves.

None. But William Blair's Matt Phipps notes the study was powered for a 40% reduction in relative risk of progression or death at final analysis — which implies the interim effect ran bigger than that. His comparator: Zegfrovy, as monotherapy against chemo, cut progression risk by 35%. So this walks into a market where J&J's Rybrevant franchise did more than $700 million in 2025, and the FDA is already reviewing zipalertinib second-line with a decision expected by February 27th.

The company it disturbs most hasn't got a drug approved yet. ArriVent has pivotal firmonertinib data coming within months, and its shares dipped as much as 7% in morning trading on the Taiho news.

You think that reaction was premature.

I think it was reflexive. Cantor's Li Watsek made the point I'd make — it's too early to size the threat, and in exon 20 the differentiator has never really been magnitude of response. It's tolerability. Patients on these regimens discontinue for skin and GI toxicity, not for lack of efficacy. A combination that wins on PFS and a monotherapy that wins on side-effect burden can both hold real share, because prescribers are choosing between them patient by patient, not once at a formulary meeting.

That's the read that survives contact with the clinic.

It's the read that survives contact with a patient who has already been on chemo.

And then the smallest study of the week produced the widest separation.

A 69-point placebo-adjusted margin.

They gave up twelve points to double the interval.

And they took that trade deliberately — the Phase 3 planned for the first half of next year runs quarterly dosing against placebo, not the stronger schedule. In a disease where the standard of care is a phlebotomy chair, dosing convenience isn't a nice-to-have, it's the entire value proposition. Mean phlebotomies came in at 0.2 per patient versus 2.1 on placebo, and the safety signal was two investigator-reported grade 1 anemia cases.

On the more usable arm. That distinction is the week in a sentence — everyone here bet that an earlier or softer signal was enough to act on. And that's exactly why the Lilly story sits where it does. At one end of that spectrum, a regulator accepts a surrogate endpoint from a randomized trial with confirmation already running. At the other end, a wellness clinic accepts nothing at all and sells the injection anyway. Same question. Catastrophically different answers.

Under the radar this week, and it's the quietest story with the sharpest contrast: the UK's MHRA granted Rhythm Pharmaceuticals expanded marketing authorization for IMCIVREE — setmelanotide — in acquired hypothalamic obesity, adults and children four and older, with orphan drug designation alongside it. Backed by the Phase 2 and Phase 3 TRANSCEND data on BMI and hunger control, published in the New England Journal.

Which meaningfully broadens the eligible population in that market. And Rhythm says it's working with the NHS on coverage guidance — that's the step that converts an authorization into revenue. The financial frame hasn't moved, though: $71.26 million in second-quarter revenue against a net loss of $104.94 million, on one commercial asset. The stock closed Friday, essentially flat.

Flat is the right reaction to a UK label expansion. What's not flat is the strategic point underneath it — acquired hypothalamic obesity is obesity with a named cause. Hypothalamic injury or impairment. That's why an orphan designation and a regulator-negotiated access pathway are even on the table.

Precisely defined patients, a regulator in the loop, a payer conversation — versus 14,000 listings and no label at all. Both of those are obesity medicine in 2026.

And the read for anyone building here is that mechanism-defined populations are where regulatory leverage still lives. It's a slower business than the GLP-1 franchises. It's also the one where the evidence, the label, and the price stay tethered to each other — and after the week we just had, that tether looks like an asset, not a constraint.

Looking at the week ahead — I'll be honest about the calendar. There's no dated catalyst in the next five days. What there is, is a board that just got a lot of new markers on it.

The nearest real one is Bristol Myers Squibb's confirmatory progression-free survival data out of EXCALIBER, expected this year. That readout answers whether an MRD-based accelerated approval was a precedent the agency meant to set, or an exception it narrows quietly afterward.

Then ArriVent's pivotal firmonertinib data in the next few months, the FDA decision on second-line zipalertinib by February 27th, Silence's full Phase 2 results at an upcoming medical congress ahead of a Phase 3 start in the first half of next year — and Lilly's retatrutide application, planned for next year.

So the quiet stretch is the useful one. Every competitive assumption in exon 20 lung cancer and in second-line myeloma gets repriced between now and February. The teams doing that work in a slow August are the ones not rewriting forecasts in a panic in February.

What I'm carrying into the week is that exclusion criterion in EXCALIBER — because I think it becomes the entire conversation the moment community hematologists start putting genuinely CD38-exposed patients on that regimen. Have a good week, everyone.

Four different rooms, one decision, and not one of them chose to wait. Follow the show on Spotify, Apple Podcasts, or wherever you listen — you'll start every weekday with this.